Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00407537 |
To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Amlodipine besylate/atorvastatin calcium single pill combination |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study |
Official Title: | A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice |
Estimated Enrollment: | 1968 |
Study Start Date: | March 2007 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Caduet: Experimental
Open label caduet added to usual care regimen followed by investigators.
|
Drug: Amlodipine besylate/atorvastatin calcium single pill combination
Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
|
Ages Eligible for Study: | 35 Years to 79 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Pfizer CT.gov Call Center | 1-800-718-1021 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A3841047 |
Study First Received: | December 1, 2006 |
Last Updated: | December 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00407537 |
Health Authority: | Czech Republic: State Institute for Drug Control |
Calcium, Dietary Vascular Diseases Atorvastatin Amlodipine Hypertension |
Antimetabolites Vasodilator Agents Molecular Mechanisms of Pharmacological Action Antilipemic Agents Calcium Channel Blockers Enzyme Inhibitors Cardiovascular Agents |
Anticholesteremic Agents Antihypertensive Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions Membrane Transport Modulators Therapeutic Uses Cardiovascular Diseases |